Safety Study of Human Milk Oligosaccharides in Healthy Adults

NCT ID: NCT05516225

Last Updated: 2022-08-25

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

32 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-09-29

Study Completion Date

2017-02-13

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

First-in-human phase 1 study conducted in healthy adult male and female volunteers to determine the safety and tolerability of increasing doses of PBCLN-003, which are concentrated human milk oligosaccharides (HMO).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PBCLN-003, 1.8 g daily in 3 divided oral doses for 7 days

Group Type EXPERIMENTAL

PBCLN-003

Intervention Type DRUG

Human Milk Oligosaccharide Concentrate

PBCLN-003, 3.6 g daily in 3 divided oral doses for 7 days

Group Type EXPERIMENTAL

PBCLN-003

Intervention Type DRUG

Human Milk Oligosaccharide Concentrate

PBCLN-003, 9 g daily in 3 divided oral doses for 7 days

Group Type EXPERIMENTAL

PBCLN-003

Intervention Type DRUG

Human Milk Oligosaccharide Concentrate

PBCLN-003, 18 g daily in 3 divided oral doses for 7 days

Group Type EXPERIMENTAL

PBCLN-003

Intervention Type DRUG

Human Milk Oligosaccharide Concentrate

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PBCLN-003

Human Milk Oligosaccharide Concentrate

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Body mass index (BMI) between 18.5 and 24.9 kg/m2
* Age between 18 and 50 years old
* No diagnosed medical conditions
* No significant change to diet in the 2 weeks prior to enrollment
* Agreement to use contraception for female subjects

Exclusion Criteria

* Lactose intolerance
* Pregnancy
* Lactation
* Enrollment in another clinical study
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Prolacta Bioscience

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

WCCT Global, LLC

Cypress, California, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

References

Explore related publications, articles, or registry entries linked to this study.

Jacobs JP, Lee ML, Rechtman DJ, Sun AK, Autran C, Niklas V. Human milk oligosaccharides modulate the intestinal microbiome of healthy adults. Sci Rep. 2023 Aug 31;13(1):14308. doi: 10.1038/s41598-023-41040-5.

Reference Type DERIVED
PMID: 37652940 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

16-CLN-003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Metformin to Augment Low Milk Supply (MALMS) Study
NCT02179788 COMPLETED PHASE1/PHASE2
Drug Excretion in Breast Milk
NCT06056583 RECRUITING PHASE4